Contact us
Expertise in real world data
Why Oxon
Publications
OXON's record of being associated with top quality publications provides clients with the reassurance that they will receive scientific rigour in the design, analysis, interpretation of their studies as well as high quality reports and manuscripts:
· Others

N Qizilbash, I Méndez, and R Sanchez-de la Rosa. 2012. “Benefit-Risk Analysis of Glatiramer Acetate for Relapsing-Remitting and Clinically Isolated Syndrome Multiple Sclerosis.” Clinical therapeutics 34(1): 159–176.e5.

R Alonso, J Fernández De Bobadilla, I Méndez, P Lázaro, N Mata, and P Mata. 2012. “Cost-Effectiveness of Managing Familial Hypercholesterolemia Using Atorvastatin-Based Preventive Therapy.” Rev. Esp. Cardiol. 61(4).

BT Blak, HT Smith, M Hards, A Maguire, and V Gimeno. 2012. “A Retrospective Database Study of Insulin Initiation in Patients with Type 2 Diabetes in UK Primary Care.” Diabetic medicine 29(8): e191–8.

JR Arribas, F Pulido, P Lázaro, I Méndez. 2011. “Estudio Farmacoeconómico de Lopinavir/ritonavir En Monoterapia En El Ensayo Clínico OK04.” PharmacoEconomics Span Res Art 8(3): 85–97.

N Qizilbash, and I Méndez. 2011. “Trends in Utilization and off-Label Use of Polyethylene Glycol 4000 Laxatives and the Prevalence of Constipation in Children in France.” Clinical and experimental gastroenterology 4: 181–88.

I Méndez, P Lázaro, X Carbonell-Estrany, and J Figueras-Aloy. 2010. “Calidad de Vida En Lactantes Nacidos Prematuros Según Ingresos Por Infección Respiratoria.” An Pediatr (Barc) 73: 121–31.

BT Blak, K Wilson, M Metcalfe, A Maguire, and M Hards. 2010. “Evaluation of Varenicline as an Aid to Smoking Cessation in UK General Practice – a THIN Database Study.” Current Medical Research and Opinion 26(4): 861–70.

N Qizilbash. 2009. “Exaggerated Benefits of Rosuvastatin Compared with Other Statins.” Pharmacoepidemiology and drug safety 18(5): 425–26.

A Maguire, BT Blak, and M Thompson. 2009. “The Importance of Defining Periods of Complete Mortality Reporting for Research Using Automated Data from Primary Care.” Pharmacoepidemiology and drug safety 18(1): 76–83.

C Koro, MO Sowell, M Stender, and N Qizilbash. 2008. “The Risk of Myopathy Associated with Thiazolidinediones and Statins in Patients with Type 2 Diabetes: A Nested Case-Control Analysis.” Clinical therapeutics 30(3): 535–42.

M Cunnington, D Webb, N Qizilbash, D Blum, A Mander, MJ Funk, and J Weil. 2008. “Risk of Ischaemic Cardiovascular Events from Selective Cyclooxygenase-2 Inhibitors in Osteoarthritis.” Pharmacoepidemiology and drug safety 17(6): 601–8.

M Emberton, JM Fitzpatrick, M Garcia-Losa, N Qizilbash, and B Djavan. 2008. “Progression of Benign Prostatic Hyperplasia: Systematic Review of the Placebo Arms of Clinical Trials.” BJU international 102(8): 981–86.

C Varas-Lorenzo, A Maguire, J Castellsague, and S Perez-Gutthann. 2007. “Quantitative Assessment of the Gastrointestinal and Cardiovascular Risk-Benefit of Celecoxib Compared to Individual NSAIDs at the Population Level.” Pharmacoepidemiology and drug safety 16(4): 366–76.

C Varas-Lorenzo, LA Garcia Rodriguez, A Maguire, J Castellsague, and S Perez-Gutthann. 2007. “Use of Oral Corticosteroids and the Risk of Acute Myocardial Infarction.” Atherosclerosis 192(2): 376–83.

D Grosset, L Taurah, DJ Burn, D MacMahon, A Forbes, K Turner, A Bowron, R Walker, L Findley, O Foster, K Patel, C Clough, B Castleton, S Smith, G Carey, T Murphy, J Hill, U Brechany, P McGee, S Reading, G Brand, L Kelly, K Breen, S Ford, M Baker, A Williams, J Hearne, N Qizilbash, and KR Chaudhuri. 2007. “A Multicentre Longitudinal Observational Study of Changes in Self Reported Health Status in People with Parkinson’s Disease Left Untreated at Diagnosis.” Journal of neurology, neurosurgery, and psychiatry 78(5): 465–69.

I Méndez, P Lázaro, J Vidal, L Carreño, A Montero, and D Samper. 2007. “Eficiencia En El Manejo de La Lumbalgia En Atención Primaria Con Tramadol Sólo O Combinado Con Paracetamol: Evaluación Coste/efectividad.” PharmacoEconomics Span Res Art 4(2): 59–70.

J Fernández de Bobadilla, CC Gómez, JA Gómez-Jerique, P Lázaro, I Méndez, and M García Vargas. 2007. “Coste Por Año de Vida Ganado Con Atorvastatina 10 Mg En Pacientes Hipertensos Españoles En Riesgo Moderado: Evaluación Económica Del Estudio ASCOT-LLA Con Costes Españoles.” PharmacoEconomics Span Res Art 4(1): 11–24.

C Koro, S Barrett, and N Qizilbash. 2007. “Cancer Risks in Thiazolidinedione Users Compared to Other Anti-Diabetic Agents.” Pharmacoepidemiology and drug safety 16(5): 485–92.

N Qizilbash, J Birks, J Lopez Arrieta, S Lewington, and S Szeto. 2007. “WITHDRAWN: Tacrine for Alzheimer’s Disease.” Cochrane database of systematic reviews (3): CD000202.

M Bhatia, SC Howard, TG Clark, R Neale, N Qizilbash, MFG Murphy, and PM Rothwell. 2006. “Apolipoproteins as Predictors of Ischaemic Stroke in Patients with a Previous Transient Ischaemic Attack.” Cerebrovascular diseases 21(5-6): 323–28.

C Varas-Lorenzo, AM Rueda de Castro, A Maguire, and M Miret. 2006. “Prevalence of Glucose Metabolism Abnormalities and Cardiovascular Co-Morbidity in the US Elderly Adult Population.” Pharmacoepidemiology and drug safety 15(5): 317–26.

FM Kovacs, M Gestoso, MT Gil del Real, J López, N Mufraggi, and I Méndez. 2003. “Risk Factors for Non-Specific Low Back Pain in Schoolchildren and Their Parents: A Population Based Study.” Pain 103(3): 259–68.

F Gil, I Méndez, A Sirgo, G Llort, I Blanco, and H Cortés-Funes. 2003. “Perception of Breast Cancer Risk and Surveillance Behaviours of Women with Family History of Breast Cancer: A Brief Report on a Spanish Cohort.” Psycho-oncology 12(8): 821–27.

N Qizilbash, SL Lewington, and JM Lopez-Arrieta. 2002. “Corticosteroids for Acute Ischaemic Stroke.” Cochrane database of systematic reviews (2): CD000064.

J Karnon, and N Qizilbash. 2001. “Economic Evaluation alongside N-of-1 Trials: Getting Closer to the Margin.” Health economics 10(1): 79–82.

M Emre, and N Qizilbash. 2001. “Experimental Approaches and Drugs in Development for the Treatment of Dementia.” Expert opinion on investigational drugs 10(4): 607–17.

FM Kovacs, V Abraira, P Lázaro, and I Méndez. 2000. “Evaluación de La Evidencia Científica, Actualización Médica Y Divulgación Sanitaria En Internet.” Rheuma 3: 43–52.

F Gil, A Sirgo, and I Méndez. 2000. “Mal Manejo de Información Diagnóstica En Pacientes Con Cáncer: Calidad de La Información Y Factores Asociados.” Rev Oncología 2(1): 33–36.

N Qizilbash. 1998. “Are Risk Factors for Stroke and Coronary Disease the Same?” Current opinion in lipidology 9(4): 325–28.

N Qizilbash, S Duffy, CR Prentice, M Boothby, and C Warlow. 1997. “Von Willebrand Factor and Risk of Ischemic Stroke.” Neurology 49(6): 1552–56.

I Méndez, MV Zunzunegui, and F Béland. 1997a. “[The Prevalence of and Factors Associated with Falls in Older Persons Living in the Community].” Medicina clínica 108(4): 128–32.

I Méndez, MV Zunzunegui, and F. Béland. 1997b. “Prevalencia Y Factores Asociados a Las Caidas En Personas Mayores Residentes En La Comunidad.” Med.Clin.Barc. 108(4): 128–33.

SA Bashir, SW Duffy, and N Qizilbash. 1997. “Repeat Measurement of Case-Control Data: Corrections for Measurement Error in a Study of Ischaemic Stroke and Haemostatic Factors.” International journal of epidemiology 26(1): 64–70.

N Qizilbash, and J M López Arrieta. 1996. “[Stroke and Cholesterol].” Revista clínica española 196(6): 347–48.

JM López Arrieta, and N Qizilbash. 1996. “[Evidence-Based Medicine: Systematic Reviews. The Cochrane Collaboration].” Medicina clínica 107(15): 581–85.

N Qizilbash 1995. “Fibrinogen and Cerebrovascular Disease.” European heart journal 16 Suppl A: 42–5; discussion 45–6.

N Qizilbash, SW Duffy, and TE Rohan. 1991. “Repeat Measurement of Case-Control Data: Correcting Risk Estimates for Misclassification due to Regression Dilution of Lipids in Transient Ischemic Attacks and Minor Ischemic Strokes.” American journal of epidemiology 133(8): 832–38.

N Qizilbash, and D Bates. 1987. “Incidence of Motor Neurone Disease in the Northern Region.” Journal of epidemiology and community health 41(1): 18–20.

 

< 12 >
Copyright © 2013 Oxon All Rights Reserved - Late phase CRO